Loading stock data…
AXSM
$206.53-1.22 (-0.59%)
Pre-Market$208.26+1.73 (+0.84%)· Last close May 1
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Axsome Therapeutics, Inc. in the Healthcare sector is trading at $206.53. The stock is currently near its 52-week high of $217.00, remaining 40.0% above its 200-day moving average. Technical signals show overbought RSI of 75 and bullish MACD crossover, explaining why AXSM maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 75) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$206.53
Potential Upside
5%
Whystock Fair Value$216.86
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus21 analysts
Mean target$235.85+14.2%
Range$198.82 – $281.00
Fundamentals
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextrometho...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$9.45B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.47
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-279.63%
Volume
Today's trading volume
1.64M
Recent News
Axsome Wins FDA Nod For Expanded Use For Auvelity Beyond Depression
The U.S. Food and Drug Administration (FDA) on Thursday approved Axsome Therapeutics Inc.'s Auvelity (dextromethorphan HBr and bupropion HCl) for agitation tied to dementia due to Alzheimer's disease, marking a new option for a condition affecting a large share of patients. The company highlighted that agitation—ranging from restlessness to verbal and physical aggression—occurs in up to 76% of individuals with Alzheimer's disease. The condition remains one of the most challenging and costly aspe
Why Axsome Therapeutics Stock Jumped Over 20% in April
Axsome shares reached an all-time high last month, and there might be more to come.
Palantir, Nvidia Partner CoreWeave Headline Earnings Calendar; Lithium Play In Spotlight
Palantir and Nvidia partner CoreWeave head into earnings next week. Lithium play Albemarle is in a base ahead of earnings.
Axsome Therapeutics Wins FDA Nod for Auvelity in Alzheimer’s Agitation, Launch Set for June
Axsome Therapeutics (NASDAQ:AXSM) announced that the U.S. Food and Drug Administration has approved Auvelity for the treatment of agitation associated with dementia due to Alzheimer’s disease, expanding the product’s indications beyond major depressive disorder. The approval and the company’s commer
Summit’s ‘self-inflicted’ stumble; Esperion’s take-private deal
Summit’s decision to conduct an interim analysis of a closely watched trial backfired. Elsewhere, Axsome got a much-needed label expansion and an FDA committee sided against an AstraZeneca breast cancer medicine.